文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

低剂量强度与标准剂量强度连续性肾脏替代治疗:系统评价与荟萃分析

Lower versus standard dose-intensity continuous renal replacement therapy: a systematic review and meta-analysis.
PubMed 文献 · Crit Care · 2026-03-27
一句话结论在需CRRT的AKI危重成人中,低剂量强度(<20 mL/kg/hr)与标准剂量强度相比ICU死亡率无显著差异,证据确定性极低;极低剂量(<13 mL/kg/hr)与90天死亡率风险升高相关。

该系统评价与荟萃分析检索MEDLINE、Embase、CINAHL和Cochrane Library(建库至2025年9月19日),纳入14项研究(3项RCT、11项队列),共5318例接受CRRT的AKI成人。主要暴露为低剂量强度CRRT(<20 mL/kg/hr),对照为指南导向标准剂量强度(≥20–40 mL/kg/hr),主要终点为ICU死亡率。低剂量强度与ICU死亡率降低相关(OR 0.77,95%CI 0.60–0.98,p=0.04,I²=26.9%,证据确定性极低),但Hartung-Knapp Sidik-Jonkmann模型敏感性分析显示两组无差异(OR 0.77,95%CI 0.55–1.08,p=0.10)。极低剂量亚组(<13 mL/kg/hr)90天死亡率风险升高(OR 1.72,95%CI 1.31–2.24,p<0.001,I²=0%,证据确定性极低)。

要点

  • 低剂量强度CRRT(<20 mL/kg/hr)与标准剂量强度(≥20–40 mL/kg/hr)相比,ICU死亡率OR 0.77(95%CI 0.60–0.98),但敏感性分析未达统计学显著(OR 0.77,95%CI 0.55–1.08,p=0.10),证据确定性极低。
  • 极低剂量强度亚组(<13 mL/kg/hr)与90天死亡率风险升高相关(OR 1.72,95%CI 1.31–2.24,p<0.001,I²=0%,证据确定性极低)。
  • 两组在透析时长、出院时透析依赖、住院时长和机械通气时长方面无显著差异。
  • 纳入的3项RCT为中等偏倚风险,多数队列研究为严重偏倚风险,总体证据确定性极低。
  • 作者认为这些发现支持进一步研究低剂量强度CRRT的影响。

适用人群与场景

  • 成人急性肾损伤(AKI)接受连续性肾脏替代治疗(CRRT)的危重患者。
  • 纳入研究类型为随机对照试验(RCT)和观察性研究。

诊断标准与关键阈值

  • 低剂量强度CRRT定义为<20 mL/kg/hr。
  • 指南导向标准剂量强度CRRT定义为≥20–40 mL/kg/hr。
  • 极低剂量强度亚组定义为<13 mL/kg/hr。

研究设计与关键结果

  • 系统评价与荟萃分析,纳入14项研究(3项RCT、11项队列),共5318例接受CRRT的AKI成人。
  • 低剂量强度CRRT(<20 mL/kg/hr)与标准剂量强度(≥20–40 mL/kg/hr)相比,ICU死亡率OR 0.77(95%CI 0.60–0.98,p=0.04,I²=26.9%,证据确定性极低)。
  • 基于Hartung-Knapp Sidik-Jonkmann模型的敏感性分析显示两组ICU死亡率无差异(OR 0.77,95%CI 0.55–1.08,p=0.10)。
  • 极低剂量强度亚组(<13 mL/kg/hr)与90天死亡率风险升高相关(OR 1.72,95%CI 1.31–2.24,p<0.001,I²=0%,证据确定性极低)。
  • 两组在透析时长、出院时透析依赖、住院时长和机械通气时长方面无显著差异。
  • RCT为中等偏倚风险,多数队列研究为严重偏倚风险。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析,纳入3项RCT和11项队列研究。
  • 证据确定性采用GRADE方法评估,主要结局ICU死亡率为极低确定性。
  • RCT为中等偏倚风险,多数队列研究为严重偏倚风险。
  • 局限:作者结论指出证据确定性极低,支持进一步研究低剂量强度CRRT的影响。

对床旁实践的改变

  • 作者认为这些发现支持进一步研究低剂量强度CRRT的影响;原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: We conducted a systematic review and meta-analysis to evaluate clinical outcomes of lower continuous renal replacement therapy (CRRT) dose-intensity compared with guideline-directed standard dose-intensity CRRT. METHODS: A comprehensive search of MEDLINE, Embase, CINAHL, and the Cochrane Library was performed from inception to September 19, 2025. Eligible studies included randomized controlled trials (RCTs) and observational studies of adults with acute kidney injury (AKI) receiving CRRT. The primary exposure was delivered lower dose-intensity CRRT (< 20 mL/kg/hr) compared with guideline-directed standard dose-intensity CRRT (≥ 20–40 mL/kg/hr). The primary outcome was intensive care unit (ICU) mortality. Certainty of evidence was assessed using the GRADE approach. (CRD420251135606) RESULTS: Fourteen studies (3 RCTs, 11 cohorts) comprising 5,318 patients were included. RCTs had moderate risk of bias, whereas most cohort studies had serious risk. Lower CRRT dose-intensity was associated with decreased ICU mortality (6 studies) compared with standard dose-intensity (OR 0.77; 95% CI 0.60–0.98; p = 0.04; I2 = 26.9%; very low certainty). However, sensitivity analysis based on a Hartung-Knapp Sidik-Jonkmann model showed no difference in ICU mortality between groups (OR 0.77 [95% CI; p = 0.10, 0.55–1.08]). There were no significant differences between groups for dialysis duration, dialysis dependence at discharge, hospital LOS, or mechanical ventilation duration. In a subgroup analysis, a very low dose-intensity group (< 13 mL/kg/hr) was associated with an increased risk in 90-day mortality (OR 1.72; 95% CI 1.31–2.24; p < 0.001, I2 = 0%; very low certainty). CONCLUSION: Among critically ill adults with AKI receiving CRRT, lower dose-intensity therapy was not associated with increased ICU mortality. Other key clinical endpoints were comparable, based on very low certainty of evidence. These findings support further research to investigate the impact of lower CRRT dose-intensity.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Lumlertgul N, Kusirisin P, Kung JY, et al. Lower versus standard dose-intensity continuous renal replacement therapy: a systematic review and meta-analysis. Crit Care. 2026. PMID: 41896891. doi:10.1186/s13054-026-05987-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。